PAION AG is a publicly listed specialty pharmaceutical company headquartered in Aachen (Germany) with further sites in Cambridge (United Kingdom) and New Jersey (USA). PAION's lead substance, remimazolam, is an intravenous ultra-short-acting benzodiazepine sedative/anesthetic currently in Phase III clinical development for procedural sedation. Remimazolam is designed to complement and improve currently available treatment options for patients requiring sedation and anesthesia. PAION is focusing its clinical development activities on remimazolam according to PAION's vision to become an acknowledged “PAIONeer” in sedation and anesthesia.
What does PAIONeering mean to us? PAIONeering means engineering the medical future, forging new paths and setting benchmarks. We have short lines of communication that make it easy to take decisions and respond quickly. A true PAIONeer is not a lone warrior, but rather a committed team player who knows that the only way to achieve our ambitious goals is to do it together. We expect flexibility and a hands-on working style from our employees. There is no room for coveting status at PAION - our work is about responsibility, achievement and room for growth.
Market capitalization (16-Oct-2020)
Closing stock price (16-Oct-2020)
When was Paion founded?
Paion was founded in 2000.
Who are Paion key executives?
Paion's key executives are Wolfgang Sohngen and Mariola Sohngen.
How many employees does Paion have?
Paion has 32 employees.
Who are Paion competitors?
Competitors of Paion include Biofrontera, ObsEva and BTG.
Where is Paion headquarters?
Paion headquarters is located at 10 Martinstraße, Aachen.
Where are Paion offices?
Paion has offices in Aachen, Mönchengladbach and Cambridge.
How many offices does Paion have?
Paion has 3 offices.
Receive alerts for 300+ data fields across thousands of companies